Rituximab-induced autoimmune hepatitis: A case study and literature review

Polymnia Galiatsatos, Sarit Assouline, Adrian Gologan, Nir Hilzenrat

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.

Original languageEnglish
Pages (from-to)381-386
Number of pages6
JournalCanadian Liver Journal
Issue number4
StatePublished - 1 Jan 2020
Externally publishedYes


  • Autoimmune hepatitis
  • Drug-induced liver injury
  • Idiopathic drug-induced liver injury
  • MALT lymphoma
  • Necro-inflammatory hepatitis
  • Rituximab

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Rituximab-induced autoimmune hepatitis: A case study and literature review'. Together they form a unique fingerprint.

Cite this